{"name":"ReveraGen BioPharma, Inc.","slug":"reveragen-biopharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPWllGZ01sWTljVXpyWHZpNHIxYVdDcDgyZ0xhNS1qTkIwTjYyUGxOcHFuTy1Pcms2OEE4a3pBNkd0a3JxM2Nsakd5M3lYbHc0bEtfdTI4NlY3b1B3MGVmN3JRWDRtTTJ3dkhWRU12QVlHOGpSZTNlUjY5YmRkck1VWmJ3UllDckF6T09VVWZKdUh0RWY1d19B?oc=5","date":"2026-04-07","type":"pipeline","source":"openPR.com","summary":"Competitive Landscape: Leading Companies and New Entrants in the Duchenne Muscular Dystrophy Drugs Market - openPR.com","headline":"Competitive Landscape: Leading Companies and New Entrants in the Duchenne Muscular Dystrophy Drugs Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNM3F3cnhfQi12TlVXUHFjNzAybmViSzh5NEdOTWxaMm1qeTNVX09GSy13UVMzY0lfVXNZajRfNmdHLU0xOEpEbVhSdTZMSjN4RjFlRnpscnZRRVdhRmV3dXJscEYtb1lfVWFWSnRUNjFCTUJ4cnhpUng4QjFpWXFDekFuc0M1aGNBUjYyWWtheFNkdw?oc=5","date":"2025-01-16","type":"pipeline","source":"pharmaphorum","summary":"Santhera preps UK Duchenne drug launch after NICE says yes - pharmaphorum","headline":"Santhera preps UK Duchenne drug launch after NICE says yes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxNTE1mMEtFS2xNbTRIV055TVBuZ0hSNm9iOEZPX0w4aE9LR3ZxeFh6a2RIS01LTW9tc0VXU0JKVmR4dEVPNDlJQ2stMmRHQnBXLTlvUmhKYkRWWXJRd3FtTVJoS2llcjBOc3g5X09SQXpRbG9oYWN1clI3SnFoeWV5SC1pUDk2bnBNcnh0WVYzQVJuVWt4U1hpR19HTHQxS1NIN2RhZWx5eGZkV3JVbVVSdjF4Nnd5czRQSG9TU0F6WTFwOFRmOWtERHhIVjJZNk9MRWVTX09Wd3VieU8wcmFxRkl6czlCWjZuZnlDeDdFV25USzVmTHhIa2pXSzZEd2RGd1R5dHhrVDRmeC12cUJXU0x3aw?oc=5","date":"2025-01-16","type":"pipeline","source":"GlobeNewswire","summary":"Santhera Pharmaceuticals Provides Update on Royalty - GlobeNewswire","headline":"Santhera Pharmaceuticals Provides Update on Royalty","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE13eW90VFBnSkIzbzRPVWw3NEVOaUNKLTdBNFJjOC1ZTzdGWUdSRGVaTExXVWo4VEFlQnNEeEVaQUU5b1poOVFTYV9WeUU4WHkyVkVkRUVMLXZZY1hFVnZna2J5RVV0b25VLUFZQVpiZklfbjZYbWpubHZn?oc=5","date":"2023-11-22","type":"trial","source":"Clinical Trials Arena","summary":"Agamree for the Treatment of Duchenne Muscular Dystrophy, US - Clinical Trials Arena","headline":"Agamree for the Treatment of Duchenne Muscular Dystrophy, US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQN3hGLTE0amRtMndNYUtvMk83MGRmaEhRcjQ3YUtLdVN4eWdoVHdJbmxSM3c1dFgzRVk3YkFYc0MtUkY3cmtTcUpFdkdCS3NGTlVDVWtNNk16dW1jVTVUTjRaSGZ5N05oUUVJdS0wdkhveXNLQWV0OXRVLUJVRXI4d2s5RDJfZkRBOERqT2NFeDl6MWhWU1JINHBzUmZnRkJZejBKVTFKOVM4NkgwMl8yUTI0YktmbXdJTkJwQVZ2WE12N0NxOHNkNVN4aHo4bTE0?oc=5","date":"2023-10-27","type":"regulatory","source":"Binghamton University","summary":"Binghamton researchers get FDA approval for drug to treat world’s most common neuromuscular genetic disease - Binghamton University","headline":"Binghamton researchers get FDA approval for drug to treat world’s most common neuromuscular genetic disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQOGZBUTNhOWt1R0lEUFQxd2ROaGpYSkRXOWtuUHVIdlFoWGFTQ0dqNGNGbkZINm5wNjFNZlRrcHpnbUQtN082b3VLQmVjZlJjSzlZd3dSX0N3Q0sxTXRINlNMblRGeWMyeFBReXhCOVlnZEVhOEFJaFNkbHlSV2gtQ3B5YkFraVdNNjItMTU2Yl9OXy04SWxzaVlkRG1LNUJwcTNGNGctQTVaRGI0SlFDd21JMEYzcDRQeVozQzR5MC0?oc=5","date":"2023-10-27","type":"regulatory","source":"innovationdistrict.childrensnational.org","summary":"FDA approves muscular dystrophy drug built on Children’s National research - innovationdistrict.childrensnational.org","headline":"FDA approves muscular dystrophy drug built on Children’s National research","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPWWFZZnhvZ05iQTFIakQybjZENE9PTzBwRUhIdE54SzdOd29PYWdkSUt3ZTg3Tm9uUERmTUVJSE16TFlsYVhseVBYOTdKV2wyOVZudGVrZ1FiQjNFZG90T1dad19UUmtZblE3Zkc1a09fSGJjU2l3TlUza2VOZVR0amptZkhUNEVfWDV1em9zSEdyN042YmhxdlBJczU3R3k2SlVXSjNzUmJ6U0pVUTNWTENKcU9NQ2M?oc=5","date":"2023-07-19","type":"pipeline","source":"Pharmaceutical Technology","summary":"Santhera and Catalyst to market DMD drug vamorolone in North America - Pharmaceutical Technology","headline":"Santhera and Catalyst to market DMD drug vamorolone in North America","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOaHZZMEk1UUstX0JyRS1yNG9KTGtmZ1RIeWY1WlEwblhLLU85LVRqY2ZlZXF3SDAtMEFJLUd1Z1lEQ2RvT0VQZFBsY0JmajhSYTJSbjZWd3JhNmVNTldmWmRjdXJJVFpic00yQTJtZ3MyVXNjWkc3MWN3eE9qTnhVZkxpVERnVy1T?oc=5","date":"2023-06-20","type":"deal","source":"pharmaphorum","summary":"Catalyst throws lifeline to Santhera with $90m Duchenne deal - pharmaphorum","headline":"Catalyst throws lifeline to Santhera with $90m Duchenne deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQRXNIb2s4ZzRHRXdES0JaaWs3TmY2NW5LMjJrMGFXb0oyemxHeWpLS1dmOFRzTTVNUmpwUlEtVzJZWTJMVUd1MVFhWkp4TjBmcUo1ZjhGdjUzUXlvM1BPM1BCNmZJRXpkd1kwS045NHRuU0d0RWRkYnVfbGlaTVJiRkxpYjUwdGJhaklrZUdEUFE0NGhWWF9GVlJiWVY4QjM1ZGxRYUJ6Ml83YXo3c1E?oc=5","date":"2020-11-02","type":"trial","source":"BioSpace","summary":"Santhera Slashes Workforce in Half After Phase III DMD Failure - BioSpace","headline":"Santhera Slashes Workforce in Half After Phase III DMD Failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQbjUtYTh2cEgySmMxdzNGT0llbC1zWnVsRjRISVJ6Nm1ZWldmbTVjRjRxSDR3VkdweWtkMWZ2Y0xOcEExOXpJZ2ZGcmRCb0U5NWhBbE5SUGh1VUxBSWNyWHJxMUR5M0xpOXU1bzJoS292WW9IX2dKMXNyWFJkaDdUdmM2YzVpanVmTHhDWA?oc=5","date":"2020-09-03","type":"pipeline","source":"Pharmaceutical Technology","summary":"Santhera obtains exclusive licence to DMD drug vamorolone - Pharmaceutical Technology","headline":"Santhera obtains exclusive licence to DMD drug vamorolone","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}